Torthaí cuardaigh - G. Charpentier

Beachtaigh na torthaí
  1. 1
    Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

    Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus de réir André Scheen, G. Charpentier, Carl Johan Östgren, Åsa Hellqvist, Ingrid Gause‐Nilsson

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

    Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-M... de réir Coralie Amadou, Sylvia Franc, Pierre‐Yves Benhamou, Sandrine Lablanche, Erik Huneker, G. Charpentier, A. Penfornis

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    One‐year real‐world performance of the <scp>DBLG1</scp> closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany

    One‐year real‐world performance of the <scp>DBLG1</scp> closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany de réir Pierre‐Yves Benhamou, Alice Adenis, Hocine Lebbad, Yousra Tourki, Maria‐Belen Heredia, Bernhard Gehr, Sylvia Franc, G. Charpentier

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Implication of the Pro12Ala polymorphism of the PPAR-gamma 2gene in type 2 diabetes and obesity in the French population

    Implication of the Pro12Ala polymorphism of the PPAR-gamma 2gene in type 2 diabetes and obesity in the French population de réir Maya Ghoussaini, Stephen Eyre, Stéphane Lobbens, G. Charpentier, Karine Clément, Marie‐Aline Charles, M. Tauber, Jacques Weill, Philippe Froguel

    Foilsithe / Cruthaithe 2005
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

    Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials de réir Bo Åhrén, Stephen L. Atkin, G. Charpentier, Mark Warren, John Wilding, Stephen Birch, Anders G. Holst, Lawrence A. Leiter

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies

    The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies de réir Stéphane Cauchi, Kevin T. Nead, Hélène Choquet, Fritz Horber, Natascha Potoczna, Beverley Balkau, Michel Marre, G. Charpentier, Philippe Froguel, David Meyre

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

    Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial de réir Andrew Ahmann, Matthew Capehorn, G. Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G. Holst, Miriam Annett, Vanita R. Aroda

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Efficacy of a Hybrid Closed-Loop Solution in Patients With Excessive Time in Hypoglycaemia: A Post Hoc Analysis of Trials With DBLG1 System

    Efficacy of a Hybrid Closed-Loop Solution in Patients With Excessive Time in Hypoglycaemia: A Post Hoc Analysis of Trials With DBLG1 System de réir Pierre‐Yves Benhamou, Alice Adenis, Yousra Tourki, Sylvie Pou, Stéphanie Madrolle, Sylvia Franc, Dulanjalee Kariyawasam, Jacques Beltrand, David C. Klonoff, G. Charpentier

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Genetic Analysis of <i>ADIPOR1</i> and <i>ADIPOR2</i> Candidate Polymorphisms for Type 2 Diabetes in the Caucasian Population

    Genetic Analysis of <i>ADIPOR1</i> and <i>ADIPOR2</i> Candidate Polymorphisms for Type 2 Diabetes in the Caucasian Population de réir Martine Vaxillaire, Aurélie Dechaume, Valérie Vasseur-Delannoy, Saida Lahmidi, Vincent Vatin, Frédéric Leprêtre, Philippe Boutin, Serge Herçberg, G. Charpentier, Christian Dina, Philippe Froguel

    Foilsithe / Cruthaithe 2006
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Hospital stays and costs of telemedical monitoring versus standard follow-up for diabetic foot ulcer: an open-label randomised controlled study

    Hospital stays and costs of telemedical monitoring versus standard follow-up for diabetic foot ulcer: an open-label randomised controlled study de réir Dured Dardari, Sylvia Franc, G. Charpentier, L. Orlando, Elise Bobony, Marie Bouly, I. Xhaard, Zohra Amrous, Khadijatou Ly Sall, B. Detournay, A. Penfornis

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

    Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial de réir John Wilding, G. Charpentier, Priscilla Hollander, Guillermo González-Gálvez, Chantal Mathieu, Frank Vercruysse, Keith Usiskin, Ga‐Lai Law, Simon Black, William Canovatchel, Gary Meininger

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Impact of Common Type 2 Diabetes Risk Polymorphisms in the DESIR Prospective Study

    Impact of Common Type 2 Diabetes Risk Polymorphisms in the DESIR Prospective Study de réir Martine Vaxillaire, J Veslot, Christian Dina, Christine Proença, Stéphane Cauchi, G. Charpentier, Jean Tichet, Frédéric Fumeron, Michel Marre, David Meyre, Beverley Balkau, Philippe Froguel

    Foilsithe / Cruthaithe 2007
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system

    Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system de réir Jean‐Pierre Riveline, J. Teynié, S. Belmouaz, Sylvia Franc, Dured Dardari, Marc Bauwens, Valérie Caudwell, Stéphanie Ragot, Frank Bridoux, G. Charpentier, R. Maréchaud, Samy Hadjadj

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Ketosis-Prone Type 2 Diabetes in Patients of Sub-Saharan African Origin

    Ketosis-Prone Type 2 Diabetes in Patients of Sub-Saharan African Origin de réir Franck Mauvais‐Jarvis, Eugène Sobngwi, Raphaël Porcher, Jean‐Pierre Riveline, Jean-Philippe Kévorkian, Christian Vaisse, G. Charpentier, Pierre-Jean Guillausseau, Patrick Vexiau, Jean‐François Gautier

    Foilsithe / Cruthaithe 2004
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Quality of Care of People With Type 2 Diabetes in Eight European Countries

    Quality of Care of People With Type 2 Diabetes in Eight European Countries de réir Margaret Stone, G. Charpentier, Kris Doggen, Oliver Kuß, Ulf Lindblad, Christiane Kellner, John J. Nolan, Agnieszka Pazderska, Guy E.H.M. Rutten, Marina Trento, Kamlesh Khunti

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Insulin Infusion Set Use: European Perspectives and Recommendations

    Insulin Infusion Set Use: European Perspectives and Recommendations de réir Dorothee Deiss, Peter Adolfsson, Marije Alkemade-van Zomeren, Geremia B. Bolli, G. Charpentier, Claudio Cobelli, Thomas Danne, A. Girelli, Heiko Mueller, Carol A. Verderese, Éric Renard

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    Insulin‐based strategies to prevent hypoglycaemia during and after exercise in adult patients with type 1 diabetes on pump therapy: the <scp>DIABRASPORT</scp> randomized study

    Insulin‐based strategies to prevent hypoglycaemia during and after exercise in adult patients with type 1 diabetes on pump therapy: the <scp>DIABRASPORT</scp> randomized study de réir Sylvia Franc, A. Daoudi, A. Pochat, M. Petit, Caroline Randazzo, C. Petit, Martine Duclos, A. Penfornis, Eric Pussard, D. Not, Elsa Heyman, François Koukoui, Chantal Simon, G. Charpentier

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients

    The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients de réir G. Charpentier, Pierre‐Yves Benhamou, Dured Dardari, Annie Clergeot, Sylvia Franc, P Schaepelynck-Bélicar, Bogdan Catargi, V. Melki, Lucy Chaillous, Anne Farret, Jean‐Luc Bosson, A. Penfornis

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Transcription Factor <i>TCF7L2</i> Genetic Study in the French Population

    Transcription Factor <i>TCF7L2</i> Genetic Study in the French Population de réir Stéphane Cauchi, Stephen Eyre, Christian Dina, Hélène Choquet, Chantal Samson, Sophie Gallina, Beverley Balkau, G. Charpentier, François Pattou, Volodymyr Stetsyuk, Raphaël Scharfmann, Bart Staels, Gema Frühbeck, Philippe Froguel

    Foilsithe / Cruthaithe 2006
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial

    Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial de réir Dulanjalee Kariyawasam, Carole Morin, Kristina Casteels, C. Le Tallec, Annie Sfez, Cécile Godot, Erik Huneker, Nathalie Garrec, Pierre‐Yves Benhamou, Michel Polak, G. Charpentier, Sylvia Franc, Jacques Beltrand

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: